Comparative Pharmacology
Head-to-head clinical analysis: LEVOPROME versus STELAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEVOPROME versus STELAZINE.
LEVOPROME vs STELAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenothiazine antipsychotic that blocks postsynaptic dopamine receptors (D2) in the central nervous system, particularly in the mesolimbic and mesocortical pathways; also has anticholinergic, antihistaminic, and alpha-adrenergic blocking effects.
Antipsychotic agent; blocks postsynaptic dopamine D1 and D2 receptors in the brain; also exhibits anticholinergic, alpha-adrenergic, and antihistaminergic effects.
25 to 50 mg intramuscularly every 6 to 8 hours; initial dose may be 25 to 75 mg. Maximum dose 150 mg per day.
Adults: 2-10 mg orally twice daily; maximum 40 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 24 hours (range 12–36 hours). Accumulation occurs with repeated dosing, requiring dose adjustment in hepatic impairment.
Terminal elimination half-life is approximately 24-30 hours (up to 40 hours in chronic use). Clinical context: Steady-state is reached in 5-7 days; allows once- or twice-daily dosing.
Primarily renal (approx. 70% as conjugated metabolites, <1% unchanged), with biliary/fecal excretion (approx. 20%).
Primarily renal (metabolites and unchanged drug; ~50% as metabolites); biliary/fecal excretion accounts for <20%.
Category C
Category C
Phenothiazine Antipsychotic
Phenothiazine Antipsychotic